BVR-B (biliverdin-IXβ reductase) also known as FR (flavin reductase) is a promiscuous enzyme catalysing the pyridinenucleotide-dependent reduction of a variety of flavins, biliverdins, PQQ (pyrroloquinoline quinone) and ferric ion. Mechanistically it is a good model for BVR-A (biliverdin-IXα reductase), a potential pharmacological target for neonatal jaundice and also a potential target for adjunct therapy to maintain protective levels of biliverdin-IXα during organ transplantation. In a commentary on the structure of BVR-B it was noted that one outstanding issue remained: whether the mechanism was a concerted hydride transfer followed by protonation of a pyrrolic anion or protonation of the pyrrole followed by hydride transfer. In the present study we have attempted to address this question using QM/MM (quantum mechanics/molecular mechanics) calculations. QM/MM potential energy surfaces show that the lowest energy pathway proceeds with a positively charged pyrrole intermediate via two transition states. These initial calculations were performed with His 153 as the source of the proton. However site-directed mutagenesis studies with both the H153A and the H153N mutant reveal that His 153 is not required for catalytic activity. We have repeated the calculation with a solvent hydroxonium donor and obtain a similar energy landscape indicating that protonation of the pyrrole is the most likely first step followed by hydride transfer and that the required proton may come from bulk solvent. The implications of the present study for the design of inhibitors of BVR-A are discussed.
INTRODUCTION
The biological role of the linear tetrapyrroles biliverdin-IXα and bilirubin-IXα in mammalian systems remains unclear. Vertebrates, plants and cyanobacteria use structurally related HOs (haem oxygenases) to cleave the haem macrocycle to form the green 'bile pigment' biliverdin-IXα (the transfer of reducing equivalents from NADPH to HO is via ferredoxin in plants and cyanobacteria [1] but via the flavoprotein cytochrome P450 reductase in mammals). The metabolic divergence occurs at the level of biliverdin-IXα. Plants and blue-green algae use biliverdin-IXα as a precursor for light-sensing (phytochromobilin) and lightharvesting (phycobilins) chromophores [2] . Mammals reduce biliverdin-IXα to bilirubin-IXα and the reaction is catalysed by BVR-A [biliverdin-IXα reductase; the corresponding reaction catalysed by BVR-B (biliverdin-IXβ reductase) is shown in Figure 1 ] generating an intermediate that is insoluble in aqueous solutions and which requires conjugation with glucuronic acid (this reaction is catalysed by the glucuronyltransferase UGT1A1) prior to excretion of the glucuronide into bile via the mrp2 organic anion pump [3] . In early literature, and more recently by McDonagh [4] , the question has been raised, why convert biliverdin-IXα, a non-toxic easily excretable waste product, into bilirubin-IXα, a substance that is unexcretable, neurotoxic, seeds gallstones and has to be further metabolized for disposal?
In mammalian systems bilirubin plays a major role as a physiologically significant antioxidant although we are far from a complete understanding of this phenomenon. The haem catabolic pathway is currently receiving attention in a number of fields with the observation that induction of HO-1 is cytoprotective [5, 6] .
Attempts to relate this to production of the immediate product biliverdin-IXα [7, 8] and/or subsequent reduction to bilirubin-IXα [9] or to a redox-cycling mechanism between these two linear tetrapyrroles [10] are unresolved. With regard to redox protection there is now good evidence [11] that low serum bilirubin-IXα is associated with a high risk of CAD (coronary artery disease). The corollary, that slightly elevated serum bilirubin-IXα is protective against CAD, has received support in studies showing that Gilberts patients (who have a less-effective promoter for UGT1A1 and are therefore unable to conjugate bilirubin effectively with glucuronic acid) do not suffer from CAD [12, 13] . The antioxidant activity of bilirubin was first suggested to be of physiological significance by Ames and co-workers [14] although the mechanism remains unclear. Several reports have suggested that lipid hydroperoxides may be reduced to the corresponding alcohol and that bilirubin may be oxidized to biliverdin during this process. In model in vitro systems this reaction is not stoichiometric and clearly more work is needed to define this process in vivo. It has been proposed [10] that biliverdin-IXα and bilirubin-IXα are involved in a protective redox cycle where lipid hydroperoxidelinked oxidation of bilirubin-IXα to biliverdin-IXα is coupled with BVR-A maintaining protective levels of bilirubin-IXα. These conclusions were reached on the basis that BVR-A mRNA knockdown cells are highly sensitive to H 2 O 2 compared with control cells.
Mammals maintain relatively high levels of circulating bilirubin-IXα and excrete this in bile predominantly as a conjugate with glucuronic acid. This reaction takes place almost exclusively in the liver. It is the delayed expression of UGT1A1 at birth that results in an inability to access the mrp2 pump so that levels Abbreviations used: BVR-A, biliverdin-IXα reductase; BVR-B, biliverdin-IXβ reductase; BVRI, BVR-A inhibitor; CAD, coronary artery disease; DFT, density functional theory; FMN, flavin mononucleotide; HO, haem oxygenase; MM, molecular mechanics; PES, potential energy surface; QM, quantum mechanics. 1 To whom correspondence should be addressed (email tmantle@tcd.ie). of unconjugated bilirubin-IXα rise in the liver and eventually reflux back into plasma resulting in the transiently elevated levels of bilirubin-IXα seen in neonatal jaundice. Other vertebrates (fish, birds, reptiles and amphibia) excrete mainly biliverdin-IXα. Biliverdin-IXα is used for egg shell pigmentation by several bird species and also circulates, sometimes at high concentrations, in the plasma of various fish and lizards. The corollary, that these species do not express BVR-A, is not the case and we have reported studies on BVR-A from salmon [15] and Xenopus tropicalis [16] . Turkey red-cell cytosol expresses BVR-A activity that we have partially purified on ion-exchange chromatography [17] , whereas the chicken genome contains putative BVR-A sequences on the basis of an analysis of ESTs (expressed sequence tags) [18] . The basis of the difference in the biliverdin-IXα/bilirubin-IXα ratio between mammals and other vertebrates is unclear.
Although the higher levels of bilirubin-IXα seen in neonatal jaundice are toxic (see below), the delayed expression of UGT1A1 may be a physiological mechanism to boost the antioxidant system at a time when the lumen of the lung is exposed to a high oxygen tension. The link between the possible antioxidant role of bilirubin-IXα and the cytoprotective role played by induction of HO-1 have stimulated studies that have recently revealed some fascinating effects of biliverdin-IXα. For example, Bach and co-workers [19] [20] [21] have presented intriguing evidence that administration of biliverdin-IXα is cytoprotective for heart, colon and liver in animal transplantation studies. In a striking report Bach and co-workers [21] have shown that short-term treatment (3 weeks) with biliverdin-IXα is sufficient to induce tolerance in a recipient to the donor heart for 120 days. The introduction of an allogeneic third heart at 120 days was rejected whereas the introduction of a third syngeneic heart was accepted, clearly indicating tolerance [21] . The doses of biliverdin-IXα used in these studies are relatively high (50 µM) and require repeated administration. Co-administration of a BVRI (BVR-A inhibitor) should allow lower doses and/or less frequent administration of biliverdin-IXα, to provide cytoprotection during organ transplantation.
BVR-A is therefore a potential pharmacological target in two areas, the first in the treatment of neonatal jaundice and the second as an adjunct mechanism to allow lower doses of biliverdin-IXα to be used during organ transplantation.
Attempts to promote BVR-A as a pharmacological target have been hampered by the lack of crystal stuctures of BVR-A with bound biliverdin-IXα. Crystal structures of rat and human BVR-A complexed with NADH and NADP + respectively [22, 23] Both enzymes BVR-A and BVR-B exhibit pronounced substrate inhibition with 'biliverdin' as the variable substrate (BVR-B cannot use biliverdin-IXα as a substrate, although it is a potent inhibitor) and both exhibit the same stereospecificity of hydride transfer from NADH [24, 25] .
Figure 4 Proposed mechanisms for BVR-B
The proposed concerted and two-step mechanism are illustrated. PH, protonation followed by hydride transfer; HP, hydride transfer followed by protonation.
The proposed mechanism of BVR-B is suggested to be either a concerted reaction [4] or a two-step mechanism ( Figure 4 ). In principle this could involve hydride transfer from the nicotinamide C 4 position to the biliverdin C 10 , forming a pyrrolic anion, and then subsequent protonation would yield bilirubin. Alternatively, protonation of the pyrrolic nitrogen could occur first followed by hydride transfer from the nicotinamide to the C 10 of a carbocation intermediate to form bilirubin. However, the exact source of the proton for these mechanisms is presently unknown. The crystal structures of BVR-B revealed the presence of a histidine residue (His 153 ) in the active site [24] . It is proposed that His 153 could act as the proton source for the 'biliverdin' substrates or, alternatively, the proton could be donated from bulk solvent [24] .
In the present paper we report a study in which we have used both computational and experimental approaches in order to gain insights into the BVR-B mechanism. To do this we have combined a QM/MM (quantum mechanics/molecular mechanics) investigation with mutagenesis studies. Hybrid QM/MM methods [26] are becoming an increasingly important tool for investigating the mechanisms of enzymes [27] . There are many advantages to using the QM/MM approach for modelling enzyme mechanisms. These include its ability to demonstrate catalytic functions of active-site residues, to identify alternative reaction intermediates and to examine other important enzyme interactions, such as the role of binding residues. Using QM/MM it is possible to determine optimized transition-state species, free energies for reactions and quantum effects such as tunnelling [28] . These are examples of properties that can be either difficult or impossible to measure in the wet laboratory. The transition-state species of an enzyme mechanism have particular relevance for the development of new inhibitors and drug design, as potent inhibitors often mimic the transition state of the enzyme.
In the present study we can define the probable mechanism as protonation of the pyrrole nitrogen atom prior to hydride transfer to the C 10 position. This mechanism will probably also hold for BVR-A, which allows us to suggest that structural analogues that cannot be protonated at the 'pyrrolic' nitrogen may bind tightly The structures of the two verdins for which there are ternary complex structures (mesobiliverdin-IVα and biliverdin-IXα) are shown together with the structure for biliverdin-IXβ in (a). In (b) these are idealized as cartoons to illustrate the orientation of the four pyrrole rings in the active site together with the various orientations of the two proprionate side chains. The top and bottom cartoons of (b) have NADPH adjacent to the reducible C 10 , whereas in the middle panel the linear tetrapyrrole is rotated 90 • so that the C 10 position is too far from the C 4 of NADPH to accept a hydride.
without forming catalytically competent complexes and therefore function as potent BVRIs.
EXPERIMENTAL

Initial rate kinetics of the wild-type and H153A and H153N mutants
The initial rate kinetics with NADPH and with FMN or biliverdin-IXδ as the second substrate were conducted spectrophotometrically monitoring the rate of oxidation of NADPH at 340 nm. Assays were conducted at 30
• C in 100 mM sodium phosphate (pH 7.2) [24] . When biliverdin-IXδ was used as the substrate, the assay mix contained, in addition, 37 µM BSA. Initial rate data with FMN as the second substrate were fitted to a rectangular hyperbola and the kinetic constants K m NADPH , K m FMN and k cat were determined by the method of Florini and Vestling [29] . Initial rate data with biliverdin-IXδ as the variable substrate were fitted to the equation for partial substrate inhibition [30] .
Computational methods
Model building
The Michaelis complex was built using the crystal structures of BVR-B in complex with NADP(H) and the mesobiliverdin-IVα substrate as a template (PDB:1HE3). The major difference between mesobiliverdin-IVα and biliverdin-IXβ are in the positions of the proprionate side chains relative to the active site of BVR-B (see Figure 5 ). To build the ternary complex of BVR-B with biliverdin-IXβ, the A, D, C and B rings of mesobiliverdin-IVα were used as a template for the B, A, D and C rings of biliverdin-IXβ. The positioning of the side-chain propionates was guided by the crystal structure of BVR-B in complex with NADP(H) and biliverdin-IXα, which has a similar propionate arrangement on the C and D pyrroles to biliverdin-IXβ (see Figure 5 ). The substrate was modified to biliverdin-IXβ using the QUANTA program (Accelrys). This provided us with the initial model of the BVR-B in complex with NADPH and biliverdin-IXβ.
QM/MM setup
In the present study two different models were treated with QM/ MM. The original model used His 153 as the proton donor and the later model used a hydroxonium ion as the proton donor. The QM regions consisted of the imidazolium side chain of His 153 or the hydroxonium ion, rings A and D of biliverdin-IXβ and the nicotinamide moiety of NADPH. Both models included large QM regions as they required elements from the substrate, NADPH and the proton donor, therefore a link atom approach [31, 32] was applied to choose the QM regions and to treat the boundary between the QM and MM regions. Four HQ-type link atoms [33] were used for QM atoms covalently bonded to MM atoms. Electrostatic, van der Waal and bonded interactions between these regions were also included. The final models and QM atom numbers are shown in Table 1 . The methods used to model the QM region were the semi-empirical AM1 [34] and PM3 [35] methods. Calculations were performed using an inner unrestrained reaction region of 16 Å radius with the remaining shell of the system fixed.
System preparation
All preparations were carried out using the CHARMM program [36] (version 27b2) using the CHARMM22 all-atom parameters for proteins [37] and nucleotides [38] . The system was based on a 25 Å radius sphere chosen with the QM/MM simulation sphere in mind. The centre of the sphere was the oxygen of the NADPH nicotinamide ribose moiety (NO4 ). Hydrogens were built on to the heavy atoms and crystallographic waters using the HBUILD function [39] in CHARMM. The system was then minimized using harmonic restraints on the main-chain and sidechain atoms of 50 and 25 kcal · mol −1 · Å −1 (1 kcal ≈ 4.184 kJ) respectively. The system was then solvated with a pre-equilibrated 60 Å cube of TIP3P model waters [40] (modified for use with CHARMM [37] ). Water molecules outside the system sphere and closer than 2.8 Å to existing heavy atoms were deleted. The water molecules were minimized and 10 pico-s of equilibration molecular dynamics at 300 K with the protein atoms fixed. Stochastic boundary conditions [41] were applied and Langevin MD with a friction coefficient of 62 ps −1 for water oxygens were used for equilibration.
Reaction modelling
The mechanisms of BVR-B were modelled by calculating a PES (potential energy surface), an approach which has been shown to perform well for other enzyme reactions [42, 43] ). The PES was calculated in 0.1 Å steps of the reaction co-ordinates using a harmonic restraint of 5000 kcal · mol −1 · Å −2 . At each step the geometry was optimized with ABNR (Adopted Basis Newton-Raphson) [36, 44] minimization until convergence (0.01 kcal · mol −1 · Å −2 gradient tolerance). Atoms further than 16 Å from the centre of the system were also restrained to their initial co-ordinates using harmonic force constants based on model B-factors [41] .
Additional hydroxonium restraint
For some of the steps in the initial modelling of the hydroxonium donor PES, the hydroxonium was observed to donate its additional protons during the optimization. Therefore the PES was also performed using an additional harmonic restraint of 5000 kcal · mol −1 · Å −2 on the two other protons of the hydroxonium.
High-level energy corrections
Single-point DFT (density functional theory) corrections were performed on the final energy profile of the hydroxonium mechanisms modelled with AM1/CHARMM22 and PM3/CHARMM22. Structures generated from the two semi-empirical QM/MM potential energy surfaces were chosen and corrected using the B3LYP method with a 6-311 + G* basis set. The calculations were performed using the JAGUAR [45] program version 6.0. Previous work performed with hybrid QM/MM methods has shown that corrections can be important to account for the potential shortcomings with the semi-empirical methodologies [46, 47] and have been shown to give results comparable with those observed from full ab initio QM/MM calculations [43, 48] . Possible pitfalls associated with energy minimization starting from a single protein structure have been discussed [49] . We have shown previously that an adiabatic mapping/energy minimization approach is useful for understanding basic features of enzyme mechanisms [50, 51] .
RESULTS AND DISCUSSION
Calculations with His 153 donor
Our initial observations based on the BVR-B structures [24] suggested a possible role for His 153 as the proton donor for the BVR-B mechanism. The potential energy surfaces shown in Figure 6 indicate a mechanism of proton transfer followed by hydride transfer. The potential energy surfaces from both methods (AM1/ CHARMM22 and PM3/CHARMM22) agree in identifying the same mechanism to be favoured. The lowest energy pathway from the biliverdin substrate (R) to bilirubin product (P) proceeds with a protonated positively charged intermediate (I PH ) via two transition states (TS PH1 and TS PH2 ). The alternative concerted and stepwise mechanisms of hydride transfer before protonation via a negatively charged pyrrolic anion intermediate (I  HP ) , are shown to be energetically unfavourable (i.e. they have significantly higher barriers). Figure 7 shows the arrangement of the intermediate 
H153A and H153N mutants
The QM/MM studies show that if His 153 is the source of the proton, then a mechanism involving protonation of the pyrrole preceding hydride transfer best agrees with the data. To test this hypothesis we constructed two mutants where His 153 was replaced with an alanine (H153A) or asparagine (H153N) residue. This was carried out using the Stratagene QuikChange ® Kit and the mutation was verified by complete sequencing in both directions. This confirmed that the desired mutation had been achieved and that no additional mutations were introduced. Examination of the initial rate kinetics for the wild-type and both H153A and H153N mutants (see Figure 9 ) showed clearly that His 153 was not required for catalytic activity. The K m NADPH and K m FMN were modified slightly; however, the k cat for the H153N mutant (0.17 s −1 ) and the H153A mutant (0.06 s −1 ) were only slightly reduced when compared with the wild-type (0.23 s −1 ). In contrast there was a significant effect on the apparent K m biliverdin−IXγ which increased as did the substrate inhibitory apparent K i . This result suggests that another amino acid residue or solvent water molecule must be the source of the proton. However our earlier inspection of the crystal structure suggested that His 153 was the only candidate within range to donate a proton to the pyrrole nitrogen. For any other side chain to be a candidate, considerable conformational changes in the structure would be required. The only other alternative is that the proton is received from bulk solvent. We therefore favour a model where a solvent water molecule is the source of the proton.
Calculations with hydroxonium donor
As experimentally testing the possibility of a water molecule as the proton source is difficult, we performed further QM/MM calculations to investigate this hypothesis. Preliminary calculations with neutral water as a proton donor showed this mechanism to be unlikely, as expected. Therefore we chose to use a hydroxonium ion for further calculations. In the hydroxonium model the His 153 was treated in MM as doubly protonated and charged. It was decided to keep the His 153 protonated after the results of the mutagenesis experiments suggested that it may still play an active role in the mechanism. In addition calculations were also performed using restraints on the protons to ensure that the hydroxonium ion did not independently donate a proton during our calculations. The tested mechanism is shown in Figure 10 .
The results of the grid searches for the water donor are shown in Figure 11 . The AM1/CHARMM22 and PM3/CHARMM22 surfaces for a hydroxonium ion donor infer the same mechanistic order as previously observed in the His 153 surfaces. The calculated potential energy surfaces again show a clearly preferred order for the mechanism, consisting of proton transfer (R • . Unlike the AM1/CHARMM22 profile, the PM3/CHARMM22 profile showed a minimum state of the reactant complex that was proceeded by a small transition-state barrier, indicating that a first transition state (TS PH1 ) may still exist in the hydroxonium mechanism, in this case of 1.8 kcal · mol −1 .
The structures for the biliverdin substrate (R), the bilirubin product (P), the protonated positively charged intermediate (I  PH ) and the  two transition states (TS  PH1 , TS  PH2 ) are shown in Figure 12 . The contributions of individual residues on the key species of the hydroxonium donor AM1/PM3//CHARMM22 surfaces are shown in Figures 13 and 14 . This type of analysis allows for identification of important residues involved in stabilization of the various species [43, 52] . Figure 13 shows the average change in potential energy when each residue is removed from the systems of the key species (R, TS PH1 , I PH , TS PH2 , P) identified by QM/MM, over increasing distance from the system's centre of mass. The major contributor in all cases was His 153 and to a lesser extent His 132 and Arg 124 . Examining the potential energy changes in the key species for these residues ( Figure 14) shows that His 153 has the major effect on the QM region and was involved in stabilizing the intermediate (I PH ) the most, and the reactants (R) the least, for AM1 and PM3. Further examination of the structures showed that initially the His 153 was involved in hydrogen bonding with the nicotinamide moiety of NADPH and changed conformation to hydrogen bond with the water molecule after the biliverdin was protonated.
Corrections to the hydroxonium donor PES
DFT corrections were performed for the QM regions of the structures (R, TS  PH1 , I PH , TS PH2 , P) of the hydroxonium mechanism PES using B3LYP [53] with a 6-311 + G* basis set. The correction energy profiles descend overall (see Figure 15 ) agreeing with a proton before hydride transfer mechanism, with a relative E of − 14.9 kcal · mol −1 (B3LYP//AM1-CHARMM22) and − 19.9 kcal · mol −1 (B3LYP//PM3-CHARMM22) for the proton transfer, and of − 70.4 kcal · mol −1 (B3LYP//AM1-CHARMM22) and − 34.5 kcal · mol −1 (B3LYP//PM3-CHARMM22) for the hydride transfer. As mentioned previously, semi-empirical methods can often overestimate barriers and perform poorly for geometries and stabilities of some functional groups [46, 47] . Further work at high levels is needed to properly identify and characterize these species.
Conclusions/revised mechanism
The use of a combined study with both experimental and computational elements has allowed valuable insights into the This shows B3LYP/6-311 + G * //AM1/CHARMM22 (᭹) and B3LYP/6-311 + G * //PM3/ CHARMM22 corrected energies ( ), relative to R. mechanism of BVR-B. Our experimental results and computational calculations, including analysis of the crystal structures of BVR-B, allow us to propose a revised mechanism for BVR-B. Our revised mechanism suggests first that the preferred pathway of the mechanism involves an initial protonation of biliverdin (R) to form an intermediate species (I PH ) which is followed by subsequent hydride transfer to form bilirubin (P). This reaction is highly favourable according to the methods used in the present study. We have shown that if protonation of biliverdin is feasible, then reduction will happen efficiently in BVR-B. To demonstrate whether the mechanism is probable, further work to determine the pKa of the bound pyrrole is necessary.
Secondly, we suggest that the most likely source of proton is from bulk solvent. In addition, from our decomposition and kinetic data, we propose that His 153 may play an important stabilizing role during the reaction, although it is not directly involved or required for catalytic activity. It is possible that the His 153 is involved in Figure 16 Proposed revision to the BVR-B mechanism in which a proton transfer is followed by hydride transfer via the transition species noted the binding of the water molecule for an initial hydroxonium generation step, as observed in our structures following proton transfer to the pyrrole nitrogen the newly formed water molecule rebinds to the histidine. This could also explain our kinetic results in which, theoretically, the H153N would still be able to form a hydrogen bond whereas the H153A would not. The revised mechanism is presented in Figure 16 . There are clear implications from the present study for the design of BVRIs. It is likely that BVR-A will follow a similar mechanism of pyrrole protonation prior to hydride transfer. The construction of biliverdin analogues with C or S atoms replacing the 'central' pyrrole N atoms should facilitate the production of compounds that will bind tightly to BVR-A, but with no potential for reduction. The hypothetical transition states seen in Figures 8  and 12 also provide building blocks for the synthesis of transition state analogues. This work will be facilitated enormously by the solution of BVR-A structures in ternary complexes with NADP + and biliverdin.
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